Condition
Demyelinating Diseases
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
15 shownMusic-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNCT07759115 · 2026-08-10
RECRUITINGInstitutional Registry of Rare DiseasesNCT06573723 · 2024-07-01
RECRUITINGNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSNCT05834855 · 2023-04-01
RECRUITINGUse of a Portable Pupillometer to Detect Optic Nerve Impairment in Patients With Suspected Multiple SclerosisNCT07837050 · 2026-09-24
NOT_YET_RECRUITINGAssessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair TherapyNCT06065670 · 2026-09-15
NOT_YET_RECRUITINGIDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDEDComparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic NeuritisNCT06494228 · 2024-01-19
UNKNOWNUkulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility StudyNCT05792176 · 2023-03-27
COMPLETEDAerobic Exercise for Remyelination in Multiple SclerosisNCT04539002 · 2021-04-29
COMPLETEDHumoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or NatalizumabNCT04837651 · 2021-03-02
COMPLETEDPower Training in Older Multiple Sclerosis PatientsNCT04762342 · 2020-12-07
UNKNOWNAcute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic NerveNCT05605951 · 2020-08-15
UNKNOWNUpper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusNCT03562975 · 2018-07-23
COMPLETEDContrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis LesionsNCT03268239 · 2017-08-02
COMPLETEDAutologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple SclerosisNCT01056471 · 2010-01-01
COMPLETEDCommon interventions
Music ListeningBEHAVIORAL2Music Training InterventionBEHAVIORAL2OcrelizumabDRUG2Additional MRI sequencesDEVICE1Aerobic exerciseBEHAVIORAL1Autologous mesenchymal stem cells from adipose tissue.OTHER1Clemastine FumarateDRUG1CyclophosphamideDRUG1Education Group ControlBEHAVIORAL1Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testDEVICE1FludarabineDRUG1IDP-023DRUG1Interleukin-2DRUG1MesnaDRUG1non-interventional studyOTHER1PlaceboDRUG1Power trainingOTHER1Pupillometry measuresDIAGNOSTIC_TEST1RituximabDRUG1T-Detect COVID T-cell blood testDEVICE1
Leading sponsors
University of Texas at Austin
2
Amsterdam UMC, location VUmc
1
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
1
Centre Hospitalier Universitaire de Nice
1
Dragonfly Research, LLC
1
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul
1
Fondation Ophtalmologique Adolphe de Rothschild
1
Hospital Italiano de Buenos Aires
1
Indapta Therapeutics, INC.
1
Oregon Health and Science University
1
University Hospital, Strasbourg, France
1
University of Aarhus
1
University of California, San Francisco
1
University of South Florida
1
Trial status mix
COMPLETED6
RECRUITING3
UNKNOWN3
NOT_YET_RECRUITING2
SUSPENDED1
Phase mix
NA6
PHASE13
PHASE22
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.